Evolution of Pfdhps and Pfdhfr mutations before and after adopting seasonal malaria chemoprevention in Nanoro, Burkina Faso.

Autor: Bohissou FET; Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany.; Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso.; Centre de Recherche Entomologique de Cotonou (CREC), Cotonou, Benin., Sondo P; Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso., Inoue J; Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany., Rouamba T; Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso., Kaboré B; Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso., Nassa GJW; Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso., Kambou AES; Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso., Traoré TE; Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso., Asua V; Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany.; Infectious Diseases Research Collaboration, Kampala, Uganda., Borrmann S; Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany.; Centre de Recherches Médicales de Lambaréné, (CERMEL), Lambaréné, Gabon., Tinto H; Institut de Recherche en Sciences de la Santé (IRSS)/Clinical Research Unit of Nanoro (CRUN), Nanoro, Burkina Faso. halidoutinto@gmail.com., Held J; Institute of Tropical Medicine, University Hospital Tübingen, Tübingen, Germany. jana.held@uni-tuebingen.de.; German Center for Infection Research (DZIF), Partner Site Tübingen, Tübingen, Germany. jana.held@uni-tuebingen.de.; Centre de Recherches Médicales de Lambaréné, (CERMEL), Lambaréné, Gabon. jana.held@uni-tuebingen.de.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Oct 16; Vol. 14 (1), pp. 24224. Date of Electronic Publication: 2024 Oct 16.
DOI: 10.1038/s41598-024-75369-2
Abstrakt: Seasonal Malaria Chemoprevention consisting of monthly administration of amodiaquine/sulfadoxine-pyrimethamine to children aged 3-59 months during the transmission season could promote SP-resistance. Mutations in dihydrofolate reductase (Pfdhfr) and dihydropteroate synthase (Pfdhps) genes were assessed before and after SMC adoption in Burkina Faso. A total of 769 dried blood spots were selected from studies conducted in Nanoro, Burkina Faso, between 2010 and 2020. Of those, 299 were pre-SMC (2010-2012) and 470 were post-SMC-samples. Pfdhps and Pfdhfr genes were PCR-amplified and sequenced. A systematic review/meta-analysis of published studies conducted in Burkina Faso (2009-2023) was additionally performed. In Nanoro, the prevalence of Pfdhfr triple mutations (CIRNI) rose from 43.6% pre-SMC to 89.4% post-SMC (p < 0.0001). There was no mutation in Pfdhfr 164 and Pfdhps 540; Pfdhps A437G mutation increased from 63.9% (2010-2012) to 84.7% (2020) (p < 0.0001). The VAGKGS haplotype was 2.8% (2020). Pfdhfr/Pfdhps quintuple mutant IRN-436A437G rose from 18.6% (2010-2012) to 58.3% (2020) (p < 0.0001). Meta-analysis results from Burkina Faso showed an increase in mutations at Pfdhfr N51I, C59R, S108N, and Pfdhps A437G after SMC adoption. Post-SMC, the pyrimethamine-resistance marker prevalence increased, while the sulfadoxine-resistance marker prevalence remained stable. Detection of emerging PfdhpsVAGKGS haplotypes in 2020 underscores the importance of continuous SP-resistance monitoring.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje